Aerpio Pharmaceuticals, Inc.
Aerpio Pharmaceuticals, Inc. (ARPO) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
arpo · stock forecast · 4 analysts (3M) · FMP · updated Jul 8, 2021
Analyst Rating & Consensus
Based on 4 Wall Street analysts in the past 3 months
Buy
4 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $2.20
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $2.26 | ↑ 2.69% |
1-day model range: $2.24–$2.28. Peak: $2.28 (+2.69%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · ARPO · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2021-07-08 | HC Wainwright & Co. | Upgrade ↑ | Neutral→Buy |
| 2020-12-14 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2020-08-13 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2020-06-25 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2019-06-12 | H.C. Wainwright | Maintains | Neutral→Neutral |
| 2019-03-19 | Guggenheim | Downgrade ↓ | Buy→Neutral |
| 2019-03-19 | H.C. Wainwright | Downgrade ↓ | Buy→Neutral |
| 2019-01-18 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2018-09-19 | Guggenheim | Maintains | Buy→Buy |
| 2018-04-18 | H.C. Wainwright | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Aerpio Pharmaceuticals, Inc. (ARPO) stock. Of the recent 10 rating actions, 1 were upgrades and 2 were downgrades. 4 analysts currently cover ARPO.
Analyst Recommendation Trends
ARPO analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
—
Revenue Next Year
—
EPS This Year
—
EPS Next Year
—
EPS ForecastReported vs Estimated
Analysts forecast ARPO EPS of $— for the current fiscal year, based on estimates from 0 analysts. The ARPO revenue forecast is — for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The ARPO stock forecast is supported by two independent data sources: analyst consensus ratings from 4 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ARPO price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The ARPO short-term stock prediction for tomorrow is $2.26 (+2.69%).
Aerpio Pharmaceuticals, Inc. trades on NASDAQ under the ticker ARPO. The ARPO stock outlook for 2027 is broadly positive, supported by a Buy consensus among 50% of covering analysts.
Frequently asked questions
ARPO forecast · 8 questionsAccording to 4 Wall Street analysts, the average 12-month ARPO price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $2.20.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.